Trial reportLung2025
A Prospective Study of Safety and the Incremental Diagnostic Value of Transbronchial Cryobiopsy Incorporated into Robotic-Assisted Bronchoscopy in a Cancer Population.
Trial report in Lung, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04548830 (Safety of Transbronchial Cryobiopsy in a Cancer Population), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety of Transbronchial Cryobiopsy in a Cancer Population
Who cites it
3 citing papers in PubMed.
- Review
- Advanced Bronchoscopic Approaches to Peripheral Pulmonary Lesions: a Narrative Review of Current and Emerging Techniques.Pulmonary therapy · 2026Review
- Real-world comparison of shape-sensing robotic-assisted bronchoscopy and virtual bronchoscopic navigation for peripheral pulmonary lesions: a propensity score-matched study.Respiratory research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundShape-sensing robotic-assisted bronchoscopy (ssRAB) combined with intraoperative imaging optimizes tool-lesion relationship during the sampling of focal pulmonary lesions. Nevertheless, confirmation of tool-in-lesion status is not equivalent to diagnostic sampling. This gap may be bridged by the addition of transbronchial cryobiopsy (TBCB) to traditional transbronchial needle aspiration (TBNA) and forceps biopsy (TBFB); however, the performance of TBCB, specifically with the 1.7-mm cryoprobe, has raised significant safety concerns.
objectiveEvaluate the safety of TBCB using the 1.7-mm cryoprobe, added into ssRAB-guided TBNA and TBFB, and performed via a protocolized approach in a cancer center patient population undergoing lung biopsy for focal parenchymal pulmonary lesions. Secondary endpoints included diagnostic yield, accuracy, and TBFB vs. TBCB tissue quality measures.
methodsThis prospective, single center, single arm study, enrolled patients referred for sampling of focal pulmonary parenchymal lesions. All procedures were performed with image-guided ssRAB with prophylactic balloon occlusion. The primary endpoint was a safety composite of grade ≥ 2 bleeding, grade ≥ 2 pneumothorax, or other biopsy-related grade ≥ 3 complication. Secondary endpoints included conservative diagnostic yield, diagnostic accuracy for malignancy, and biopsy specimen quality measures.
resultsFifty-one participants were enrolled and underwent image-guided ssRAB. The primary severe adverse event rate was 0% (95% CI 0.0-7.9). The conservative diagnostic yield was 92% and the diagnostic accuracy for malignancy was 90%. TBCB was superior to forceps biopsy in measures of total specimen dimensions, diagnostic tissue area, and degree of crush artifact (P < 0.001 for all comparisons).
conclusionIn cancer patients with localized parenchymal lung lesions, the incorporation of a rigorous safety protocol into image-guided ssRAB allows for the safe acquisition of high-quality peripheral lung TBCB specimen, utilizing the 1.7-mm cryoprobe. CLINICAL
trial registrationClinicaltrials.gov identifier: NCT04548830.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.